Funding extension brings in $8M for antibody drug developer

04/1/2013 | MedCityNews.com

Theraclone Sciences secured an additional $8 million, bringing the total raised in its Series B funding round to $50 million. The Seattle biotech company is developing two antibodies for severe flu and cytomegalovirus infection.

View Full Article in:

MedCityNews.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA